Finding infections earlier is only part of the work. At IDWeek 2026, David Weber, MD, MPH, explored how broader surveillance and emerging technologies could help infection preventionists spend more time supporting safer care.
|Articles|July 1, 2004
Quidels QuickVue® Influenza A+B Test Now Available in the United States
Advertisement
SAN DIEGO -- Quidel Corporation today announced that its new QuickVue Influenza test A+B has become available in the United States. The new, CLIA-waived QuickVue Influenza A+B test provides information to aid in the differential diagnosis of acute influenza type A or B. The test provides physicians with a fast, accurate, easy-to-use method for aiding in the differential diagnosis of acute influenza type A or B. Using a nasal swab or nasal/wash aspirate, the test is designed to deliver results in 10 minutes or less and require only 30 seconds of hands-on time. Test kits can be stored at room temperature and have a 24-month shelf life from manufacture date.
Source: Quidel Corporation
Advertisement
Related to this article
Two experts give an update ahead of the first season with a new mRNA vaccine against flu.
Part 1 of 4: How emerging sterile processing leaders are redefining leadership through trust, accountability, psychological safety, and professional development.
This week in infection prevention: Kenya’s Bundibugyo virus response shows why execution, not just planning, determines outcomes, and France reported the first known human Shamonda virus infection. Our roundup also covers brucellosis, blood donor screening, and long-acting HIV antibody findings from IDWeek 2026.
At IDWeek 2026, Jimmy Chang, PhD, discussed investigational HIV antibodies TMB-365 and TMB-380, explaining their complementary mechanisms, early study findings, and ongoing evaluation as a long-acting maintenance regimen.
At IDWeek 2026, Samuel Ntow, MBChB, MPH, discussed research findings of reactive infection screening markers in 18.3% of replacement donor records from rural Ghana, highlighting opportunities for further evaluation and linkage to care.
France’s first reported human Shamonda virus infection raises questions about transmission and vulnerable patients. Explore what investigators know, what remains uncertain, and why infection preventionists should follow this emerging story.
John Rex, MD, CMO of F2G, discusses investigational olorofim’s phase 3 findings, why new antifungals are difficult to develop, and how an oral option could help patients with limited treatment choices.
Advertisement
Advertisement
Trending on Infection Control Today
1
Early Flu, Late RSV: What Infection Preventionists Should Watch This Respiratory Season
2
David Weber, MD, at IDWeek 2026: A Career of IPC and His Thoughts on Influential Research
3
ICT Weekly Rounds: Ebola Execution Gaps, a Midge-Borne Virus Jumps to Humans, and IDWeek Findings
4
The Next Generation of SPD Leadership: People First, Standards Always
5